论文部分内容阅读
目的:探讨金水宝联合奥美沙坦酯治疗早期糖尿病肾病的临床疗效。方法:选择2012年1月至2014年1月在我院治疗的86例早期糖尿病肾病患者的临床资料,进行回顾性分析。结果:观察组患者经金水宝联合奥美沙坦酯治疗,总有效率为93.02%,明显高于对照组的81.40%,经比较,P<0.05,差异具有统计学意义。观察组患者治疗后的Scr、UAE、Ualb/Cr均有明显改善,改善情况优于对照组,经比较,P<0.05,差异具有统计学意义。结论:金水宝联合奥美沙坦酯治疗早期糖尿病肾病的临床疗效确切,值得推广应用。
Objective: To investigate the clinical efficacy of Jinshuibao combined with olmesartan medoxomil in the treatment of early diabetic nephropathy. Methods: The clinical data of 86 patients with early diabetic nephropathy treated in our hospital from January 2012 to January 2014 were retrospectively analyzed. Results: The total effective rate was 93.02% in observation group treated by Jinshui Bao combined with olmesartan medoxomil, which was significantly higher than 81.40% in control group, P <0.05, the difference was statistically significant. After treatment, Scr, UAE and Ualb / Cr in the observation group were significantly improved, and the improvement was better than that in the control group. After comparison, P <0.05, the difference was statistically significant. Conclusion: The clinical efficacy of Jinshuibao combined with olmesartan medoxomil in the treatment of early diabetic nephropathy is worthy of promotion and application.